Acuta Capital Partners’s BioTelemetry, Inc. BEAT Stock Holding History

Acuta Capital Partners’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-40,000	Closed	-$1.24M	–	88
2018 Q1	$1.24M	Buy	+40,000	New	+$1.32M	0.2%	42
2016 Q3	–	Sell	-34,630	Closed	-$564K	–	84
2016 Q2	$564K	Buy	+34,630	New	+$509K	0.27%	51
2016 Q1	–	Sell	-150,322	Closed	-$1.76M	–	64
2015 Q4	$1.76M	Sell	150,322 -299,678	-67%	-$3.79M	0.84%	33
2015 Q3	$5.51M	Sell	450,000 -210,000	-32%	-$2.68M	3.19%	7
2015 Q2	$6.22M	Buy	660,000 +178,931	+37%	+$1.66M	3.85%	7
2015 Q1	$4.26M	Sell	481,069 -2,803	-0.6%	-$28.3K	3.59%	5
2014 Q4	$4.85M	Buy	+483,872	New	+$4.15M	3.28%	6

Other funds holding BEAT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acuta Capital Partners's BEAT Position: Q2 2018 in Review

Acuta Capital Partners sold out of BioTelemetry, Inc. (BEAT) in Q2 2018, closing a stake of 40,000 shares — an estimated $1.24M sold.

Acuta Capital Partners first reported a position in BEAT in Q4 2014 and held it in 7 quarters. The position peaked at $6.22M in Q2 2015. 227 funds tracked by Wall St. Rank hold BEAT as of Q2 2018.

Acuta Capital Partners reported no remaining BioTelemetry, Inc. position as of Q2 2018 after selling out during the quarter.
Acuta Capital Partners sold 40,000 BioTelemetry, Inc. shares in Q2 2018, an estimated $1.24M.
Acuta Capital Partners first reported a position in BioTelemetry, Inc. in Q4 2014 and held it in 7 quarters.
Acuta Capital Partners's BioTelemetry, Inc. position peaked at $6.22M in Q2 2015.
227 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q2 2018.

Based on Acuta Capital Partners's 13F filing for Q2 2018, filed 15 Aug 2018.